The board of directors of biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.55 per share of the company's common stock for the the third quarter of 2019.

This dividend is payable on 8 July 2019 to shareholders of record at the close of business as of 17 June 2019.

Through the company's prescription medicines, vaccines, biologic therapies and animal health products, it operate in 140 countries to deliver innovative health solutions.

According to the company, it continues to be at the forefront of research to advance the prevention and treatment of diseases including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.